Clinical Trial Goal
To find out:
- The highest dose of ITU512 that's safe to give
- If ITU512 is safe and works well to treat SCD in children, teens and adults
You may be able to join this trial if you:
- Are 12 - 55 years old
- Have SCD
- Are currently being treated with hydroxyurea
- Have a history of irregular heart beat (arrhythmia)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ITU512 is a molecular glue degrader that targets WIZ, and increases HbF.
You’ll get:
You’ll get:
- ITU512 – The dose you'll get depends on when you start the trial and how safe it has been]
- Placebo – The dose you'll get depends on when you start the trial and how safe it has been]
The clinical trial doctors will check your health for up to 4 months.
The Food and Drug Administration (FDA) has not yet approved ITU512.
Contacts
Novartis Pharmaceuticals, 1-888-669-6682, novartis.email@novartis.com
Novartis Pharmaceuticals, +41613241111
Locations
Quotient Sciences Sea ViewRECRUITING
Miami, Florida
305-644-9903
Sponsors
lead: Novartis Pharmaceuticals
